// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























3441 Abstracts

OUTCOMES OF ANTI PLA2R POSITIVE MEMBRANOUS NEPHROPATHY TREATED WITH MODIFIED PONTICELLI REGIMEN-A SINGLE CENTRE EXPERIENCE

S. Singh - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Membranous glomerulonephritis

Methylprednisolone

CLINICAL AND SAFETY OUTCOMES WITH APIXABAN VERSUS WARFARIN BY EGFR IN ADULTS WITH ATRIAL FIBRILLATION

D. Lam - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Transient Ischemic Attack

apixaban

What's Common Is Common - Well Not This Time: A Case of Primary Lung Adenocarcinoma in a 15-Year-Old Girl

K. Yaacoby-Bianu - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Pembrolizumab

A Case of Metastatic Lung Squamous Cell Carcinoma with EGFR Mutation and Excellent Response to Osimertinib

H. K. Gharib - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Pembrolizumab

Osimertinib Induced Cardiotoxicity-Two Case Reports

K. N. Parmar - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Coronary Artery Disease

Tagrisso

A Case of ALK Positive Adenocarcinoma of Unknown Primary with Good Response to Alectinib

V. L. Kankanala - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Alectinib

Prevalence and Mechanisms of Bronchiolar Mucus Plugging in COVID-19 Lung Disease

T. Kato - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Interleukin

Review Analysis of Clinical Characteristics in 185 Interstitial Lung Disease Patients Accompanied with Lung Cancer (ILD-LC)

Y. Hu - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Interstitial lung disease

N/A

Epidermal Growth Factor Receptor (EGFR) Modulates Apoptosis in Hyperoxia-Induced Lung Injury

Z. M. Harris - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Acute lung injury

N/A

CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04

Corinne Summers - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Junfang Yang - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

T-cell acute lymphoblastic leukemia

Cyclophosphamide

A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma

Carmelo Carlo-Stella - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Effect of the Neddylation Inhibitor Pevonedistat on Normal Hematopoietic Stem Cell Subsets and Immune Cell Composition

Fatemeh Majidi - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Pevonedistat

A Novel Cotinine-Based System for Switchable Chimeric Antigen Receptor T Cell Immunotherapy

Ki Hyun Kim - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematological malignancies

N/A

Donor-Derived Amphiregulin Drives CD4+ T Cell Expansion and Promotes Tissue Pathology after Experimental Allogeneic BMT

Takahiro Ito - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

amphiregulin

Non-Canonical Gli1 Activation Mediates Profibrotic Hematopoiesis-Stroma Crosstalk in MPN

Jessica E. Pritchard - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

N/A

Profiling the Cell Surface of MPN Blast Phase Suggests Unique Biology and Therapeutic Targets

Emilio Ramos - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Identification of TSC22D3 As a Novel Immune-Related Prognostic Biomarker of Acute Myeloid Leukemia

Yang Li - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Glucocorticoid

EGFR and HDAC Dual-Target Inhibitor CUDC-101 Enhances the Anti-Myeloma Effects of Bortezomib By Regulating the G2/M Cell Cycle Arrest

Wen Cao - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Bortezomib

Development of Humanized CD19-Chimeric Antigen Receptor for B Cell Malignancy

Vibhuti Vyas - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

Interferon Gamma

Copyright © 2026. QuantiNova All rights reserved